Opinion|Videos|January 5, 2024
Adverse Events Seen With JAK Inhibitors for Myelofibrosis
Author(s)Christine Cooper, RN, BSN, Aaron Gerds, MD, MS
The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Basal Cell Carcinoma Basics, From Diagnosis to Treatment
2
Covering Every FDA Oncology Approval From October 2025
3
Stage 2 Cervical Cancer: Key Facts and Updates for Patients
4
Areola Tattoos Help Patients Feel ‘As Normal as Possible’ After Breast Cancer
5
